Phase 3 Clinical Trials With Primary Completion Dates in October 2017
This is a list of Phase 3 trials with primary completion dates in October 2017 for companies with a market cap less than $1B. For complete clinical trial coverage, please see our Trial Tracker tool. It includes information on all clinical trials for publicly traded companies, screenable by stock symbol, market cap, disease, completion date, and phase.
The primary completion date is the date that the final subject was examined or received an intervention for the purposes of final collection of data for the primary outcome. It provides advance notice that a company will be announcing trial results in the near future.
|Symbol||Company||Primary Completion Date||Phase||NCT ID||Title|
|ARDX||Ardelyx, Inc.||2017-10-01||Phase 3||NCT02727751||A Long-Term Safety Study of Tenapanor for the Treatment of IBS-C|
|CPRX||Catalyst Pharmaceuticals, Inc.||2017-10-01||Phase 3||NCT02562066||Amifampridine Phosphate for the Treatment of Congenital Myasthenic Syndromes|
|EARS||Auris Medical Holding AG||2017-10-01||Phase 3||NCT02561091||AM-111 in the Treatment of Acute Inner Ear Hearing Loss|
|INSM||Insmed, Inc.||2017-10-01||Phase 3||NCT02344004||Study to Evaluate Efficacy of LAI When Added to Multi-drug Regimen Compared to Multi-drug Regimen Alone|
|MNK||Mallinckrodt plc||2017-10-01||Phase 3||NCT02132195||Adrenocorticotropic Hormone (ACTH) for Frequently Relapsing and Steroid Dependent Nephrotic Syndrome|
|NBRV||Nabriva Therapeutics plc||2017-10-01||Phase 3||NCT02813694||Study to Compare Lefamulin to Moxifloxacin for the Treatment of Adults With Pneumonia|
|TARO||Taro Pharmaceutical Industries Ltd.||2017-10-01||Phase 3||NCT02595073||Clinical Study to Evaluate the Efficacy and Safety of DSXS With Atopic Dermatitis|
|TGTX||TG Therapeutics, Inc.||2017-10-01||Phase 3||NCT02301156||Ublituximab in Combination With Ibrutinib Versus Ibrutinib Alone in Patients With Previously Treated High-Risk Chronic Lymphocytic Leukemia (CLL)|
|VICL||Vical Incorporated||2017-10-01||Phase 3||NCT01877655||A Study to Evaluate a Therapeutic Vaccine, ASP0113, in Cytomegalovirus (CMV)-Seropositive Recipients Undergoing Allogeneic, Hematopoietic Cell Transplant (HCT)|